8-K: Dermata Therapeutics Appoints Baker Tilly as New Auditor Following Merger, Prior Reports Flag Going Concern Uncertainty

Dermata Therapeutics, Inc. has appointed Baker Tilly US, LLP as its new independent registered public accounting firm, succeeding Moss Adams LLP following a merger, while noting Moss Adams' previous audit reports included a going concern uncertainty.

Summary

• Dermata Therapeutics, Inc. (the Company) was notified on June 3, 2025, that its independent registered public accounting firm, Moss Adams LLP, merged with Baker Tilly US, LLP.
• The combined audit practices now operate as Baker Tilly US, LLP, with the merger becoming effective on June 3, 2025.
• The audit committee of the Company's Board of Directors approved the appointment of Baker Tilly as the successor to Moss Adams.
• Moss Adams' audit reports on the Company's financial statements for the years ended December 31, 2024, and 2023, and internal control over financial reporting as of December 31, 2024, did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified, except for an explanatory paragraph regarding a going concern uncertainty.
• During the years ended December 31, 2024 and 2023, and the subsequent interim period through June 3, 2025, there were no disagreements with Moss Adams on accounting principles, financial statement disclosure, or auditing scope or procedure.
• Neither the Company nor anyone on its behalf consulted with Baker Tilly regarding the application of accounting principles or the type of audit opinion prior to their appointment.

Sentiment

Score: 3

Explanation: The sentiment is low due to the explicit 'going concern uncertainty' noted in the audit reports for two consecutive years, which is a severe financial red flag. While the auditor transition itself was smooth, the underlying financial health concern overshadows any procedural positives.

Positives

• The transition to Baker Tilly US, LLP as the new auditor was a result of a merger with the previous auditor, Moss Adams LLP, suggesting potential continuity in audit personnel and knowledge.
• There were no disagreements with Moss Adams on any accounting principles, financial statement disclosure, or auditing scope or procedure, indicating a smooth and cooperative relationship with the former auditor.

Negatives

• Moss Adams' audit reports for both the years ended December 31, 2024, and 2023, contained an explanatory paragraph regarding a 'going concern uncertainty,' which indicates substantial doubt about the Company's ability to continue as a going concern.

Risks

• The primary risk is the 'going concern uncertainty' explicitly noted in the audit reports for the years ended December 31, 2024, and 2023, which raises significant concerns about the Company's financial viability and ability to meet its obligations in the foreseeable future.

Future Outlook

NA

Management Comments

• The audit committee of the Company's Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company's independent registered public accounting firm.

Industry Context

This filing primarily details a change in auditing firms, a common occurrence in the accounting industry, especially due to mergers. For Dermata Therapeutics, a company likely in the biotechnology or pharmaceutical sector, the critical aspect is the 'going concern uncertainty' noted by the auditor, which is a significant indicator of financial health and can impact investor perception within the industry.

Comparison to Industry Standards

• The document does not provide specific financial or operational results for direct comparison to industry benchmarks.
• However, the presence of a 'going concern uncertainty' explanatory paragraph in audit reports for two consecutive years (2023 and 2024) indicates that Dermata Therapeutics' financial stability and operational viability are significantly below typical industry standards for a healthy, ongoing enterprise.

Corporate Governance

Stakeholder Impact

• Shareholders: The 'going concern uncertainty' could significantly erode investor confidence, potentially leading to a decline in share price and increased volatility.
• Creditors: The explicit 'going concern uncertainty' may lead creditors to reassess the Company's creditworthiness, potentially impacting lending terms or the availability of future financing.
• Employees: While not directly stated, a 'going concern' issue can create uncertainty regarding job security and the long-term stability of the Company.

Next Steps

• The Company will continue its operations with Baker Tilly US, LLP serving as its independent registered public accounting firm.
• The Company will need to address the underlying financial issues that led to the 'going concern uncertainty' noted by its auditors.

Key Dates

Recommendation

Keywords

Dermata Therapeutics, DRMA, SEC filing, 8-K, auditor change, independent registered public accounting firm, Moss Adams, Baker Tilly, going concern, financial reporting, corporate governance, Nasdaq Capital Market